# The Role of PIWI‐Interacting RNA in Urologic Carcinoma and Its Clinical Implications

## TL;DR

This paper reviews how piRNA molecules are involved in urologic cancers and their potential for clinical diagnosis.

## Contribution

The paper systematically reviews piRNA's role in urologic carcinoma and its clinical implications.

## Key findings

- piRNA regulates key signaling pathways in urologic carcinoma through m6A modification and transposable element silencing.
- piRNA exhibits tissue-specific expression in various human cancers.
- piRNA has potential applications in clinical diagnosis due to its specific expression profiles.

## Abstract

Piwi‐interacting RNA (piRNA) represents a class of small non‐coding RNA molecules, typically ranging in length from 18 to 35 nucleotides. These molecules are critically involved in the preservation of genomic integrity and the regulation of protein translation processes. Recently, emerging scholarly research indicates that piRNA exhibits tissue‐specific expression profiles within a variety of human malignancies, where they intricately regulate key signaling pathways at both the transcriptional and post‐transcriptional levels. This review systematically underscores current investigations pertaining to piRNA in urologic carcinoma (UC), elucidating the proposed regulatory mechanisms encompassing N6‐methyladenosine (m6A) modification and the silencing of transposable elements. Furthermore, we discuss the detection technology and the application of piRNA in the fields of clinical diagnosis.